A comprehensive Personal Molecular Profile
The InnVentis technology platform combines data of unprecedented quality and depth
with cutting-edge algorithms to create actionable insights:
- Cost-efficient sourcing of extremely high quality *omics analytics and clinical analytics
- Proprietary knowledge in machine learning and algorithm development
- Stringent control of sample and data collection with proprietary standard operation procedures
The goal: A platform connecting all inflammatory diseases with all routes of intervention
- Our current products and services serve drug discovery companies in Rheumatoid Arthritis (RA)
- Our mid-term vision comprises a diagnostics disease monitoring ecosystem for RA, even enabling the patient to self-monitor their personal precision treatment
- Our long-term goal is to build on the RA platform by extending it to other inflammatory conditions like Asthma, Multiple Sclerosis, and Colitis.
"One of the biggest challenges in medicine and science today
is how to interpret the vast amount of biological data
we are generating... To make these data interpretable
and clinically actionable will require new computational tools."
Craig Venter, August 2014.
is how to interpret the vast amount of biological data
we are generating... To make these data interpretable
and clinically actionable will require new computational tools."
Craig Venter, August 2014.
“The power of high-throughput omics approaches to identify previously
unrecognized patterns and trends, and drive novel hypothesis generation,
could ultimately lead to research that fundamentally changes
how we understand basic biological processes and human disease.”
Mike Synder, Prof. and Chair Stanford Genetics, InnVentis SAB in:
“Where Next for Genetics and Genomics?” PLoS Biol 2015, 13(7): e1002216. doi:10.1371/journal.pbio.1002216
unrecognized patterns and trends, and drive novel hypothesis generation,
could ultimately lead to research that fundamentally changes
how we understand basic biological processes and human disease.”
Mike Synder, Prof. and Chair Stanford Genetics, InnVentis SAB in:
“Where Next for Genetics and Genomics?” PLoS Biol 2015, 13(7): e1002216. doi:10.1371/journal.pbio.1002216